"Can I take this with my medication?" is the single most useful question anyone asks about a botanical supplement, and it is the one most often answered badly — either with a blanket reassurance or a blanket warning, neither of which is honest. Red clover (Trifolium pratense) has a genuinely interesting interaction profile: some concerns are well grounded in chemistry, one widely repeated concern has actually been tested in people and largely did not materialise, and several remain theoretical. This article separates those categories. It is written for a general reader but with enough detail to be useful to pharmacists and prescribers.
Why interactions are plausible at all
Two features of red clover's chemistry drive the whole discussion.
The first is its isoflavones — principally biochanin A and formononetin, which the body can convert to genistein and daidzein. These are phytoestrogens: their structure is close enough to 17β-estradiol that they interact, weakly, with estrogen receptors, and they have been described as possessing estrogenic properties in regulatory review.1 Anything with receptor-level activity invites questions about medicines that act on the same receptors.
The second is that red clover is not only isoflavones. The Trifolium genus carries a wider set of constituents, and the phytochemical profile differs substantially between species and between preparations.2 Coumarin derivatives are among the compounds present, and the EFSA Panel reviewing isoflavone supplements specifically noted that other bioactive components — coumestrol among them — can occur in red clover extracts.1 Coumarins are structurally adjacent to the chemistry of oral anticoagulants, which is where the best-known caution originates.
Note throughout that this is a discussion about oral supplementation. Interaction questions arise from systemic exposure, and the clinical literature here is built on capsules and tablets. Our companion article covers the broader safety picture and the oral-versus-topical distinction in detail: Red Clover Side Effects: What to Know and Who Should Be Cautious.
Coumarins, anticoagulants and bleeding risk
This is the interaction most worth taking seriously.
A review of herb-drug interactions with analgesic medicines listed red clover among the coumarin-containing herbal supplements with the potential to increase bleeding risk when combined with drugs affecting haemostasis.3 An integrative oncology monograph compiled at Memorial Sloan Kettering Cancer Center states the point directly for anticoagulants and antiplatelet agents: red clover may enhance their effects.4
For warfarin specifically, the theoretical case is easy to construct — a coumarin-containing botanical taken alongside a coumarin anticoagulant with a narrow therapeutic index and INR monitoring already in place. What does not exist, and this is worth stating plainly rather than glossing over, is a body of controlled human interaction studies quantifying the effect. The concern rests on chemistry and expert pharmacological review rather than on trial data showing a defined INR shift at a defined dose.
That combination — high potential consequence, low evidential resolution — is exactly the situation in which caution is the rational default rather than an overreaction. Anyone on warfarin or another oral anticoagulant should not start red clover without discussing it with the clinician managing their anticoagulation, and should not stop or start it silently between INR checks.
NSAIDs and antiplatelet agents
The same coumarin reasoning extends to medicines that impair platelet function. The analgesic interaction review named non-steroidal anti-inflammatory drugs, aspirin included, as the drug class of concern alongside coumarin-containing herbs such as red clover, with enhanced bleeding risk as the anticipated outcome.3
In practice this is less about a single ibuprofen tablet and more about sustained or high-dose NSAID use, low-dose aspirin taken for cardiovascular reasons, or antiplatelet therapy such as clopidogrel — and about people who have additional bleeding risk factors layered on top. It is a reasonable prompt for a pharmacist to raise at the counter when a customer buys a red clover supplement, and a reasonable thing for a patient to mention when a new antiplatelet is started.
Hormone therapy, tamoxifen and aromatase inhibitors
Here the evidence is mechanistic and, honestly, somewhat contradictory — which is itself the finding.
Biochanin A, red clover's most abundant isoflavone, has been shown in cell-based work to inhibit aromatase activity and to reduce aromatase (CYP19) expression, with an IC50 of roughly 8 µM in a transfected MCF-7 cell line.5 Aromatase is precisely the enzyme that aromatase inhibitors are prescribed to block. Whether a dietary supplement produces intracellular concentrations anywhere near those used in cell culture is an entirely separate question, and one that study does not answer — but it establishes that the pathway is not inert to red clover constituents.
On tamoxifen, the available signal comes from an animal pharmacokinetic study. Rats given oral biochanin A alongside tamoxifen showed significantly reduced area under the curve and peak plasma concentration for both tamoxifen and its active metabolite 4-hydroxytamoxifen — a decrease in exposure, notably the opposite of what the authors anticipated from biochanin A's known inhibition of CYP3A and P-glycoprotein.6 This is a rat study at a high dose and cannot be read across to humans. It does, however, undercut any confident assertion that the direction of a tamoxifen interaction is predictable.
Layer on top the receptor-level consideration: the Memorial Sloan Kettering monograph advises that people with breast cancer avoid red clover given its potential to stimulate proliferation of estrogen receptor-positive breast cancer cells.4 And note the limitation in the regulatory evidence base — the EFSA Panel observed that a current diagnosis or history of breast cancer was typically an exclusion criterion in the intervention studies it reviewed, leaving that sub-population under-represented in its assessment.1
The defensible conclusion for anyone on endocrine therapy, or with a hormone-sensitive diagnosis, is that combining it with red clover is an oncology decision, not a self-care one. The related research on estrogen receptors and menopause is covered in Red Clover and Menopause: What Research Shows.
CYP enzymes: in vitro signal, clinical reality
This section is the one most likely to change a pharmacist's mental model, because the widely circulated warning has been directly tested.
The warning first: red clover has been reported to inhibit a broad panel of cytochrome P450 enzymes in laboratory systems — CYP1A2, 2C8, 2C9, 2C19, 2D6 and 3A4 — raising the prospect of interactions with the very many drugs those enzymes metabolise.4 Taken at face value, that is an alarming list.
It has since been examined in people. A clinical pharmacokinetic study administered a standardised red clover supplement providing 120 mg of isoflavones per day to fifteen peri- and postmenopausal women, using caffeine, tolbutamide, dextromethorphan and alprazolam as probe substrates for CYP1A2, CYP2C9, CYP2D6 and CYP3A4/5 respectively. Pharmacokinetic profiles were measured at baseline and again after two weeks of supplementation. The averaged profiles showed no significant alterations and no change in area under the curve over 96 hours, and subgroup analysis by BMI, menopausal status, race and age found no differences either. The authors noted that serum isoflavones appeared primarily as conjugated metabolites, which may at least partly explain the result.7
That is a genuinely reassuring finding, and the gap between in vitro prediction and clinical outcome it illustrates is a recurring pattern in botanical pharmacology. It is also a single study, and its boundaries should be respected: fifteen participants, one standardised product at one dose over two weeks, four enzymes. It says nothing about CYP2C8 or CYP2C19, nothing about transporter-mediated interactions, nothing about other red clover preparations with different isoflavone profiles — and, importantly, nothing at all about the pharmacodynamic bleeding-risk concern discussed above, which does not operate through CYP metabolism.
The fair summary: the broad CYP-inhibition warning is not well supported by the human data that exist, while the coagulation-related caution is untouched by that study and still stands.
Surgery and planned procedures
Because the plausible mechanism concerns bleeding, planned surgery is a sensible point to review red clover use. General practice for herbal supplements is to disclose them during pre-operative assessment and to agree on whether and when to stop.
We are not aware of a validated, red-clover-specific discontinuation interval, and it would be misleading to quote one as though it were established. The right framing is procedural rather than numerical: tell your surgeon, anaesthetist or pre-operative clinic that you take it, and let them decide the timing alongside your other medicines. The same applies before dental extractions and other procedures with bleeding risk.
A practical summary
Treat as a real caution requiring clinical discussion: oral anticoagulants including warfarin; antiplatelet agents; regular or high-dose NSAIDs and aspirin; tamoxifen, aromatase inhibitors and hormone therapy; any hormone-sensitive diagnosis, past or present. Add pregnancy and breastfeeding, where the NCCIH advises that red clover supplements may be unsafe.8
Treat as largely reassured but not closed: metabolic interactions via CYP1A2, 2C9, 2D6 and 3A4, where a clinical probe-substrate study at 120 mg isoflavones per day found no significant pharmacokinetic changes.7
And treat the general principle as non-negotiable: if you take prescription medication of any kind, ask before starting a botanical supplement. The NCCIH puts it without qualification — talk with your health care provider before using any herbal product, because some herbs and medicines interact in harmful ways.8
For the wider evidence on red clover in skin and hair research, see our main guide, Red Clover Benefits for Skin, Hair and Health, and for how we source and work with the plant, our red clover ingredient page.
Frequently asked questions
Can you take red clover with warfarin?
Not without medical supervision. Red clover contains coumarin derivatives, and reviews of herb-drug interactions have identified coumarin-containing herbs as a potential bleeding-risk concern alongside drugs that affect haemostasis. Controlled human studies quantifying a warfarin interaction do not exist, so the caution rests on chemistry and expert review rather than trial data — which is a reason for care, not for dismissal. Discuss it with the clinician managing your anticoagulation.
Does red clover interact with ibuprofen or aspirin?
A published review of interactions with analgesic drugs named red clover among coumarin-containing herbal supplements that could increase bleeding risk when combined with NSAIDs, including aspirin. The concern is most relevant with sustained or high-dose NSAID use, low-dose aspirin taken for cardiovascular reasons, or existing bleeding risk factors. Mention red clover use to your pharmacist.
Does red clover affect cytochrome P450 drug metabolism?
Laboratory studies reported inhibition of several CYP enzymes, but a clinical study in fifteen peri- and postmenopausal women taking a standardised supplement at 120 mg of isoflavones daily found no significant changes in the pharmacokinetics of probe drugs for CYP1A2, CYP2C9, CYP2D6 and CYP3A4/5, and no change in area under the curve. That is reassuring within its limits: one study, one product and dose, four enzymes, two weeks.
Can I take red clover while on tamoxifen or an aromatase inhibitor?
This should be decided with your oncology team. Cell-based research found that biochanin A inhibited aromatase activity and expression, and a rat pharmacokinetic study found reduced exposure to tamoxifen and its active metabolite when biochanin A was co-administered. Neither is human evidence, but together they mean the direction and size of any interaction cannot be assumed. Guidance from a cancer centre monograph also advises people with breast cancer to avoid red clover.
Should I stop red clover before surgery?
Raise it during pre-operative assessment. Because the plausible mechanism relates to bleeding, red clover belongs on the list of supplements you disclose before surgery or dental procedures. We are not aware of an established red-clover-specific stopping interval, so let your surgeon or anaesthetist decide the timing rather than following a generic number.
This article is for general information and education only. It is not medical advice, and Minerva108 cosmetic products are not intended to diagnose, treat, cure or prevent any disease. Do not start, stop or change any medication or supplement on the basis of this article — if you take prescription medicines or are managing a health condition, please consult your doctor or pharmacist.
References
- EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA Journal 2015;13(10):4246. doi:10.2903/j.efsa.2015.4246
- Kolodziejczyk-Czepas J. Trifolium species — the latest findings on chemical profile, ethnomedicinal use and pharmacological properties. Journal of Pharmacy and Pharmacology 2016;68(7):845–861. doi:10.1111/jphp.12568
- Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy and Therapeutics 2002;27(6):391–401. doi:10.1046/j.1365-2710.2002.00444.x
- Memorial Sloan Kettering Cancer Center. Red Clover. About Herbs monograph, last updated February 2022. mskcc.org
- Wang Y, Man Gho W, Chan FL, Chen S, Leung LK. The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression. British Journal of Nutrition 2008;99(2):303–310. doi:10.1017/S0007114507811974
- Singh SP, Wahajuddin, Raju KS, Ali MM, Kohli K, Jain GK. Reduced bioavailability of tamoxifen and its metabolite 4-hydroxytamoxifen after oral administration with biochanin A (an isoflavone) in rats. Phytotherapy Research 2012;26(2):303–307. doi:10.1002/ptr.3652
- Chen L, Choi J, Leonard SW, Banuvar S, Barengolts E, Viana M, Chen SN, Pauli GF, Bolton JL, van Breemen RB. No clinically relevant pharmacokinetic interactions of a red clover dietary supplement with cytochrome P450 enzymes in women. Journal of Agricultural and Food Chemistry 2020;68(47):13929–13939. doi:10.1021/acs.jafc.0c05856
- National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health. Red Clover: Usefulness and Safety. Last updated April 2025. nccih.nih.gov